Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mesoblast Ltd Ads (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 360,671
  • Shares Outstanding, K 94,170
  • Annual Sales, $ 17,340 K
  • Annual Income, $ -35,290 K
  • 36-Month Beta 1.87
  • Price/Sales 21.72
  • Price/Cash Flow N/A
  • Price/Book 0.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -150.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.73 +2.68%
on 12/18/18
5.11 -25.05%
on 11/19/18
-1.27 (-24.90%)
since 11/16/18
3-Month
3.73 +2.68%
on 12/18/18
8.78 -56.38%
on 10/01/18
-2.32 (-37.72%)
since 09/18/18
52-Week
3.73 +2.68%
on 12/18/18
8.78 -56.38%
on 10/01/18
-2.49 (-39.40%)
since 12/18/17

Most Recent Stories

More News
Meetings Held With FDA Support Mesoblast's Planned Regulatory Filing for Commercialization of Remestemcel-L in Acute GVHD

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that recent meetings held with the United States Food and Drug Administration (FDA) support its planned regulatory filing for commercialization...

MESO : 3.83 (-4.25%)
Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China

Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering Committee (JSC) meeting for their cardiovascular partnership was held in Tianjin last...

MESO : 3.83 (-4.25%)
Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended September 30, 2018 in a webcast beginning at 4:30 pm on Thursday, November 15, 2018 EST; 8:30 am Friday, November...

MESO : 3.83 (-4.25%)
MSB : 25.86 (+3.32%)
Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its allogeneic mesenchymal precursor cell product candidate MPC-150-IM in the treatment...

MESO : 3.83 (-4.25%)
MSB : 25.86 (+3.32%)
Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership in China for Mesoblast's allogeneic mesenchymal...

MESO : 3.83 (-4.25%)
3 Biotech Stocks With Rising Estimates in the Past Month

The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.

MESO : 3.83 (-4.25%)
TRVN : 0.54 (-3.93%)
CELG : 66.63 (-2.20%)
LGND : 133.56 (+0.82%)
VRTX : 163.43 (-1.65%)
GILD : 64.84 (-0.43%)
BIIB : 294.75 (-5.86%)
Mesoblast Heart Failure Cell Therapy for Children Featured at Regenerative Symposium for Congenital Heart Disease

Mesoblast Limited (ASX:MSB, Nasdaq:MESO) today announced that Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) heart failure product candidate MPC-150-IM for use in children with hypoplastic...

MESO : 3.83 (-4.25%)
Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast's Phase 3 Trial for Acute Graft Versus Host Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast's...

MESO : 3.83 (-4.25%)
Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that Tasly Pharmaceutical Group has successfully obtained all necessary approvals, including the Safe Administration of Foreign Exchange, required...

MESO : 3.83 (-4.25%)
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting

Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate MSC-100-IV (remestemcel-L) in children with steroid-refractory acute Graft versus...

MESO : 3.83 (-4.25%)
MSB : 25.86 (+3.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade MESO with:

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

2nd Resistance Point 4.22
1st Resistance Point 4.02
Last Price 3.83
1st Support Level 3.68
2nd Support Level 3.54

See More

52-Week High 8.78
Fibonacci 61.8% 6.85
Fibonacci 50% 6.26
Fibonacci 38.2% 5.66
Last Price 3.83
52-Week Low 3.73

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar